$RNAC
Cartesian Therapeutics, Inc. Stock $rnac

$rnac Overview Financials Valuation SEC Filings Company Website

2018 Q2 Form 10-Q Financial Statement

#000145368718000030 Filed on May 09, 2018

Income Statement

Concept	2018 Q2	2018 Q1	2017 Q4
Revenue	$0.00	$0.00	$17.00K
YoY Change	-100.0%	-100.0%	-99.42%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$4.360M	$4.670M	$5.670M
YoY Change	-11.02%	20.36%	-1.56%
% of Gross Profit
Research & Development	$14.41M	$11.14M	$13.62M
YoY Change	31.04%	0.86%	23.48%
% of Gross Profit
Depreciation & Amortization	$400.0K	$200.0K	$180.0K
YoY Change	100.0%	0.0%	-28.0%
% of Gross Profit
Operating Expenses	$18.77M	$15.81M	$19.29M
YoY Change	18.07%	5.99%	14.91%
Operating Profit	-$18.77M	-$15.81M
YoY Change	18.26%	6.97%
Interest Expense	$365.0K	$350.0K	-$130.0K
YoY Change	30.82%	16.67%	-58.06%
% of Operating Profit
Other Income/Expense, Net	$8.000K	$0.00	-$140.0K
YoY Change			-275.0%
Pretax Income	-$18.80M	-$15.89M	-$19.54M
YoY Change	17.72%	5.02%	38.78%
Income Tax			$0.00
% Of Pretax Income
Net Earnings	-$18.80M	-$15.89M	-$19.54M
YoY Change	17.72%	4.98%	38.78%
Net Earnings / Revenue			-114964.71%
Basic Earnings Per Share
Diluted Earnings Per Share	-$840.8K	-$711.0K	-$876.6K
COMMON SHARES
Basic Shares Outstanding	22.35M shares	22.35M shares	22.34M shares
Diluted Shares Outstanding

Balance Sheet

Concept	2018 Q2	2018 Q1	2017 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments	$66.20M	$83.10M	$96.60M
YoY Change	-41.26%	21.31%	14.86%
Cash & Equivalents	$60.24M	$58.23M	$70.62M
Short-Term Investments	$6.000M	$24.80M	$25.90M
Other Short-Term Assets	$2.600M	$1.900M	$2.100M
YoY Change	36.84%	-34.48%	-16.0%
Inventory
Prepaid Expenses
Receivables		$63.00K	$63.00K
Other Receivables		$0.00	$0.00
Total Short-Term Assets	$68.84M	$98.68M	$98.68M
YoY Change	-39.92%	38.04%	13.67%
LONG-TERM ASSETS
Property, Plant & Equipment	$2.137M	$2.091M	$2.091M
YoY Change	0.28%	1.8%	2.15%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$2.500M	$2.700M	$0.00
YoY Change			-100.0%
Total Long-Term Assets	$4.602M	$2.420M	$2.420M
YoY Change	88.07%	2.11%	-2.62%
TOTAL ASSETS
Total Short-Term Assets	$68.84M	$98.68M	$98.68M
Total Long-Term Assets	$4.602M	$2.420M	$2.420M
Total Assets	$73.44M	$101.1M	$101.1M
YoY Change	-37.25%	36.89%	13.21%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$1.789M	$1.606M	$1.606M
YoY Change	-58.2%	21.94%	-58.63%
Accrued Expenses	$10.18M	$8.580M	$8.580M
YoY Change	18.49%	55.41%	118.82%
Deferred Revenue	$1.918M	$787.0K	$787.0K
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due			$0.00
YoY Change			-100.0%
Total Short-Term Liabilities	$13.89M	$10.97M	$10.97M
YoY Change	-30.73%	-17.52%	-19.94%
LONG-TERM LIABILITIES
Long-Term Debt	$21.20M	$21.10M	$21.00M
YoY Change	271.93%	205.8%	162.5%
Other Long-Term Liabilities	$1.104M	$1.201M	$1.201M
YoY Change	-11.68%	-90.47%
Total Long-Term Liabilities	$1.104M	$1.201M	$1.201M
YoY Change	-11.68%	-93.84%
TOTAL LIABILITIES
Total Short-Term Liabilities	$13.89M	$10.97M	$10.97M
Total Long-Term Liabilities	$1.104M	$1.201M	$1.201M
Total Liabilities	$49.18M	$47.46M	$49.29M
YoY Change	26.6%	44.83%	43.51%
SHAREHOLDERS EQUITY
Retained Earnings	-$247.2M	-$215.1M	-$216.9M
YoY Change	35.32%	29.01%	43.07%
Common Stock	$3.000K	$3.000K	$3.000K
YoY Change	200.0%	200.0%	200.0%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$21.66M	$38.98M	$51.81M
YoY Change
Total Liabilities & Shareholders Equity	$73.44M	$101.1M	$101.1M
YoY Change	-37.25%	36.89%	13.21%

Cashflow Statement

Concept	2018 Q2	2018 Q1	2017 Q4
OPERATING ACTIVITIES
Net Income	-$18.80M	-$15.89M	-$19.54M
YoY Change	17.72%	4.98%	38.78%
Depreciation, Depletion And Amortization	$400.0K	$200.0K	$180.0K
YoY Change	100.0%	0.0%	-28.0%
Cash From Operating Activities	-$16.97M	-$13.41M	-$12.67M
YoY Change	97.1%	-12.45%	-912.18%
INVESTING ACTIVITIES
Capital Expenditures	-$270.0K	$192.0K	-$150.0K
YoY Change	-32.5%	231.03%	36.36%
Acquisitions
YoY Change
Other Investing Activities	$18.95M	$1.140M	$6.250M
YoY Change	70.87%	-106.92%	-222.79%
Cash From Investing Activities	$18.68M	$945.0K	$6.110M
YoY Change	74.58%	-105.72%	-217.5%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net		$0.00
YoY Change
Debt Paid & Issued, Net		$0.00
YoY Change		-100.0%
Cash From Financing Activities	310.0K	$51.00K	5.030M
YoY Change	-99.43%	-117.47%	80.29%
NET CHANGE
Cash From Operating Activities	-16.97M	-$13.41M	-12.67M
Cash From Investing Activities	18.68M	$945.0K	6.110M
Cash From Financing Activities	310.0K	$51.00K	5.030M
Net Change In Cash	2.020M	-$12.39M	-1.530M
YoY Change	-96.39%	-61.29%	80.0%
FREE CASH FLOW
Cash From Operating Activities	-$16.97M	-$13.41M	-$12.67M
Capital Expenditures	-$270.0K	$192.0K	-$150.0K
Free Cash Flow	-$16.70M	-$13.60M	-$12.52M
YoY Change	103.41%	-11.53%	-849.7%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2016Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	59050000	USD
CY2017Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	27034000	USD
CY2018Q1	dei	Amendment Flag AmendmentFlag	false
CY2018Q1	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2018Q1	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q1
CY2018Q1	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2018
CY2018Q1	dei	Document Period End Date DocumentPeriodEndDate	2018-03-31
CY2018Q1	dei	Document Type DocumentType	10-Q
CY2018Q1	dei	Entity Central Index Key EntityCentralIndexKey	0001453687
CY2018Q2	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	22349840	shares
CY2018Q1	dei	Entity Filer Category EntityFilerCategory	Accelerated Filer
CY2018Q1	dei	Entity Registrant Name EntityRegistrantName	SELECTA BIOSCIENCES INC
CY2017Q4	selb	Accrued Audit Fees Current AccruedAuditFeesCurrent	859000	USD
CY2018Q1	selb	Accrued Audit Fees Current AccruedAuditFeesCurrent	913000	USD
CY2017Q4	selb	Accrued Collaborationand Licensing AccruedCollaborationandLicensing	1020000	USD
CY2018Q1	selb	Accrued Collaborationand Licensing AccruedCollaborationandLicensing	859000	USD
CY2017Q4	selb	Accrued Grant Refund Current AccruedGrantRefundCurrent	175000	USD
CY2018Q1	selb	Accrued Grant Refund Current AccruedGrantRefundCurrent	175000	USD
CY2017Q4	selb	Accrued Patent Fees Current AccruedPatentFeesCurrent	268000	USD
CY2018Q1	selb	Accrued Patent Fees Current AccruedPatentFeesCurrent	408000	USD
CY2017Q4	selb	Accrued Rent And Lease Incentive Payable Current AccruedRentAndLeaseIncentivePayableCurrent	72000	USD
CY2018Q1	selb	Accrued Rent And Lease Incentive Payable Current AccruedRentAndLeaseIncentivePayableCurrent	83000	USD
CY2017Q4	selb	Accrued Research And Development Costs Current AccruedResearchAndDevelopmentCostsCurrent	3578000	USD
CY2018Q1	selb	Accrued Research And Development Costs Current AccruedResearchAndDevelopmentCostsCurrent	4377000	USD
CY2017Q4	selb	Cash Cash Equivalents Restricted Cashand Restricted Cash Equivalents Current CashCashEquivalentsRestrictedCashandRestrictedCashEquivalentsCurrent	70698000	USD
CY2018Q1	selb	Cash Cash Equivalents Restricted Cashand Restricted Cash Equivalents Current CashCashEquivalentsRestrictedCashandRestrictedCashEquivalentsCurrent	58304000	USD
CY2018Q1	selb	Cash Cash Equivalents Restricted Cashand Restricted Cash Equivalents Current CashCashEquivalentsRestrictedCashandRestrictedCashEquivalentsCurrent	70698000	USD
CY2017Q4	selb	Contract With Customer Liability Deferred Revenue Current ContractWithCustomerLiabilityDeferredRevenueCurrent	787000	USD
CY2018Q1	selb	Contract With Customer Liability Deferred Revenue Current ContractWithCustomerLiabilityDeferredRevenueCurrent	959000	USD
CY2018Q1	selb	Contract With Customer Liability Deferred Revenue Current ContractWithCustomerLiabilityDeferredRevenueCurrent	787000	USD
CY2017Q4	selb	Contract With Customer Liability Deferred Revenue Noncurrent ContractWithCustomerLiabilityDeferredRevenueNoncurrent	15919000	USD
CY2018Q1	selb	Contract With Customer Liability Deferred Revenue Noncurrent ContractWithCustomerLiabilityDeferredRevenueNoncurrent	13917000	USD
CY2018Q1	selb	Contract With Customer Liability Deferred Revenue Noncurrent ContractWithCustomerLiabilityDeferredRevenueNoncurrent	14089000	USD
CY2018Q1	selb	Contractwith Customer Liability Deferred Revenue ContractwithCustomerLiabilityDeferredRevenue	14876000	USD
CY2018Q1	selb	Contractwith Customer Liability Deferred Revenue ContractwithCustomerLiabilityDeferredRevenue	14876000	USD
CY2018Q1	selb	Contractwith Customer Liability Deferred Revenue Increase From Cash Receipts ContractwithCustomerLiabilityDeferredRevenueIncreaseFromCashReceipts	0	USD
CY2018Q1	selb	Contractwith Customer Liability Deferred Revenue Revenue Recognized ContractwithCustomerLiabilityDeferredRevenueRevenueRecognized	0	USD
CY2018Q1	selb	Contractwith Customer Liability Increase From Cash Receipts ContractwithCustomerLiabilityIncreaseFromCashReceipts	0	USD
CY2018Q1	selb	Contractwith Customer Liability Other ContractwithCustomerLiabilityOther	2231000	USD
CY2018Q1	selb	Contractwith Customer Liability Other ContractwithCustomerLiabilityOther	2231000	USD
CY2018Q1	selb	Contractwith Customer Liability Other Current ContractwithCustomerLiabilityOtherCurrent	800000	USD
CY2018Q1	selb	Contractwith Customer Liability Other Increase From Cash Receipts ContractwithCustomerLiabilityOtherIncreaseFromCashReceipts	0	USD
CY2018Q1	selb	Contractwith Customer Liability Other Noncurrent ContractwithCustomerLiabilityOtherNoncurrent	1400000	USD
CY2018Q1	selb	Contractwith Customer Liability Other Revenue Recognized ContractwithCustomerLiabilityOtherRevenueRecognized	0	USD
CY2018Q1	selb	Debt Instrument Event Of Default Minimum Amount In Excess Of Indebtedness Trigger DebtInstrumentEventOfDefaultMinimumAmountInExcessOfIndebtednessTrigger	300000	USD
CY2018Q1	selb	Debt Instrument Event Of Default Minimum Assets Trigger DebtInstrumentEventOfDefaultMinimumAssetsTrigger	300000	USD
CY2018Q1	selb	Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months	22800000	USD
CY2018Q1	selb	Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months Number Of Positions DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions	10	position
CY2017Q4	selb	Deferred Rent And Lease Incentive Liability DeferredRentAndLeaseIncentiveLiability	200000	USD
CY2018Q1	selb	Deferred Rent And Lease Incentive Liability DeferredRentAndLeaseIncentiveLiability	200000	USD
CY2018Q1	selb	Defined Contribution Plan Employers Matching Contribution Vesting Period DefinedContributionPlanEmployersMatchingContributionVestingPeriod	P4Y
CY2016Q4	selb	License And Option Agreement Number Of Additional Targets For Which Other Party May Exercise Options For Additional Licenses LicenseAndOptionAgreementNumberOfAdditionalTargetsForWhichOtherPartyMayExerciseOptionsForAdditionalLicenses	4	target
CY2018Q1	selb	Number Of Collaboration Agreements Under Analysis To Quantify Impact Of Adoption NumberOfCollaborationAgreementsUnderAnalysisToQuantifyImpactOfAdoption	3	agreement
CY2018Q1	selb	Revenue Remaining Performance Obligation Percentage RevenueRemainingPerformanceObligationPercentage	0.090
CY2018Q1	selb	Tax Cutsand Jobs Act Changein Tax Rate Increase Decrease In Deferred Tax Asset TaxCutsandJobsActChangeinTaxRateIncreaseDecreaseInDeferredTaxAsset	-23400000	USD
CY2018Q1	selb	Tax Cutsand Jobs Act Valuation Allowance Deferred Tax Asset Increase Decrease Amount TaxCutsandJobsActValuationAllowanceDeferredTaxAssetIncreaseDecreaseAmount	23400000	USD
CY2018Q1	selb	Votes Per Shareof Common Stock VotesPerShareofCommonStock	1
CY2017Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	1606000	USD
CY2018Q1	us-gaap	Accounts Payable Current AccountsPayableCurrent	1789000	USD
CY2018Q1	us-gaap	Accounts Payable Current AccountsPayableCurrent	1606000	USD
CY2017Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	63000	USD
CY2017Q1	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	693000	USD
CY2018Q1	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	1153000	USD
CY2018Q1	us-gaap	Available For Sale Securities Debt Maturities Within One Year Amortized Cost AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost	24852000	USD
CY2017Q4	us-gaap	Available For Sale Securities Debt Maturities Within One Year Fair Value AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue	25940000	USD
CY2018Q1	us-gaap	Available For Sale Securities Debt Maturities Within One Year Fair Value AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue	24839000	USD
CY2017Q4	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	25940000	USD
CY2018Q1	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	24839000	USD
CY2017Q1	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	125000	USD
CY2018Q1	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	142000	USD
CY2018Q1	us-gaap	Capitalized Contract Cost Net CapitalizedContractCostNet	2600000	USD
CY2017Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	26637000	USD
CY2018Q1	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	52000	USD
CY2018Q1	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	63000	USD
CY2017Q1	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	-89000	USD
CY2018Q1	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	32000	USD
CY2017Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	8580000	USD
CY2018Q1	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	9062000	USD
CY2018Q1	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	8580000	USD
CY2017Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	4158000	USD
CY2018Q1	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	4333000	USD
CY2017Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-4420000	USD
CY2018Q1	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-4398000	USD
CY2018Q1	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-4420000	USD
CY2017Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	273128000	USD
CY2018Q1	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	274334000	USD
CY2018Q1	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	273128000	USD
CY2017Q1	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	2122966	shares
CY2018Q1	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	2834467	shares
CY2017Q4	us-gaap	Area Of Real Estate Property AreaOfRealEstateProperty	5100	sqft
CY2017Q4	us-gaap	Assets Assets	101100000	USD
CY2018Q1	us-gaap	Assets Assets	89937000	USD
CY2018Q1	us-gaap	Assets Assets	103698000	USD
CY2017Q4	us-gaap	Assets Current AssetsCurrent	98680000	USD
CY2018Q1	us-gaap	Assets Current AssetsCurrent	84984000	USD
CY2018Q1	us-gaap	Assets Current AssetsCurrent	98911000	USD
CY2017Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	0	USD
CY2018Q1	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	0	USD
CY2017Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	16000	USD
CY2018Q1	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	13000	USD
CY2017Q4	us-gaap	Available For Sale Debt Securities Amortized Cost Basis AvailableForSaleDebtSecuritiesAmortizedCostBasis	25956000	USD
CY2018Q1	us-gaap	Available For Sale Debt Securities Amortized Cost Basis AvailableForSaleDebtSecuritiesAmortizedCostBasis	24852000	USD
CY2018Q1	us-gaap	Available For Sale Debt Securities Gross Unrealized Loss AvailableForSaleDebtSecuritiesGrossUnrealizedLoss	100000	USD
CY2017Q4	us-gaap	Available For Sale Securities Debt Maturities Within One Year Amortized Cost AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost	25956000	USD
CY2018Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	58228000	USD
CY2017Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	71027000	USD
CY2018Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	58633000	USD
CY2017Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-32016000	USD
CY2018Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-12394000	USD
CY2017Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2018Q1	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2017Q4	us-gaap	Common Stock Capital Shares Reserved For Future Issuance CommonStockCapitalSharesReservedForFutureIssuance	3757059	shares
CY2018Q1	us-gaap	Common Stock Capital Shares Reserved For Future Issuance CommonStockCapitalSharesReservedForFutureIssuance	4746018	shares
CY2017Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2018Q1	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2017Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	200000000	shares
CY2018Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	200000000	shares
CY2017Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	22343254	shares
CY2018Q1	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	22349840	shares
CY2017Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	22343254	shares
CY2018Q1	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	22349840	shares
CY2017Q4	us-gaap	Common Stock Value CommonStockValue	3000	USD
CY2018Q1	us-gaap	Common Stock Value CommonStockValue	3000	USD
CY2018Q1	us-gaap	Common Stock Value CommonStockValue	3000	USD
CY2017Q1	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-14996000	USD
CY2018Q1	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-15866000	USD
CY2018Q1	us-gaap	Contract With Customer Liability ContractWithCustomerLiability	17107000	USD
CY2018Q1	us-gaap	Contract With Customer Liability ContractWithCustomerLiability	17107000	USD
CY2018Q1	us-gaap	Contract With Customer Liability Revenue Recognized ContractWithCustomerLiabilityRevenueRecognized	0	USD
CY2016Q2	us-gaap	Convertible Preferred Stock Shares Issued Upon Conversion ConvertiblePreferredStockSharesIssuedUponConversion	10126118	shares
CY2017Q1	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	0	USD
CY2018Q1	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	0	USD
CY2018Q1	us-gaap	Debt Instrument Interest Rate Effective Percentage DebtInstrumentInterestRateEffectivePercentage	0.0677
CY2017Q1	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	0	USD
CY2018Q1	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	0	USD
CY2017Q4	us-gaap	Deferred Rent Credit Noncurrent DeferredRentCreditNoncurrent	151000	USD
CY2018Q1	us-gaap	Deferred Rent Credit Noncurrent DeferredRentCreditNoncurrent	129000	USD
CY2018Q1	us-gaap	Deferred Rent Credit Noncurrent DeferredRentCreditNoncurrent	151000	USD
CY2017Q1	us-gaap	Defined Contribution Plan Cost Recognized DefinedContributionPlanCostRecognized	100000	USD
CY2018Q1	us-gaap	Defined Contribution Plan Cost Recognized DefinedContributionPlanCostRecognized	100000	USD
CY2017Q1	us-gaap	Depreciation Depreciation	175000	USD
CY2017Q1	us-gaap	Depreciation Depreciation	200000	USD
CY2018Q1	us-gaap	Depreciation Depreciation	169000	USD
CY2018Q1	us-gaap	Depreciation Depreciation	200000	USD
CY2018Q1	us-gaap	Dividends Common Stock DividendsCommonStock	0	USD
CY2017Q1	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.82
CY2018Q1	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.71
CY2017Q1	us-gaap	Effect Of Exchange Rate On Cash And Cash Equivalents EffectOfExchangeRateOnCashAndCashEquivalents	124000	USD
CY2018Q1	us-gaap	Effect Of Exchange Rate On Cash And Cash Equivalents EffectOfExchangeRateOnCashAndCashEquivalents	19000	USD
CY2017Q1	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	3875000	USD
CY2018Q1	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	4674000	USD
CY2017Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	1902000	USD
CY2018Q1	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	1441000	USD
CY2018Q1	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	-13000	USD
CY2017Q1	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	-165000	USD
CY2017Q1	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-2589000	USD
CY2018Q1	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	180000	USD
CY2017Q1	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-152000	USD
CY2018Q1	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-11000	USD
CY2017Q1	us-gaap	Increase Decrease In Accrued Liabilities And Other Operating Liabilities IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities	1413000	USD
CY2018Q1	us-gaap	Increase Decrease In Accrued Liabilities And Other Operating Liabilities IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities	404000	USD
CY2017Q1	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	57000	USD
CY2018Q1	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	0	USD
CY2017Q1	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	316000	USD
CY2018Q1	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-417000	USD
CY2017Q1	us-gaap	Interest Expense InterestExpense	300000	USD
CY2018Q1	us-gaap	Interest Expense InterestExpense	350000	USD
CY2017Q1	us-gaap	Interest Paid InterestPaid	241000	USD
CY2018Q1	us-gaap	Interest Paid InterestPaid	261000	USD
CY2017Q4	us-gaap	Interest Payable Current InterestPayableCurrent	89000	USD
CY2018Q1	us-gaap	Interest Payable Current InterestPayableCurrent	92000	USD
CY2017Q1	us-gaap	Investment Income Net InvestmentIncomeNet	113000	USD
CY2018Q1	us-gaap	Investment Income Net InvestmentIncomeNet	288000	USD
CY2017Q4	us-gaap	Liabilities Liabilities	49286000	USD
CY2018Q1	us-gaap	Liabilities Liabilities	48355000	USD
CY2018Q1	us-gaap	Liabilities Liabilities	47456000	USD
CY2017Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	101100000	USD
CY2018Q1	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	89937000	USD
CY2018Q1	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	103698000	USD
CY2017Q4	us-gaap	Liabilities Current LiabilitiesCurrent	10973000	USD
CY2018Q1	us-gaap	Liabilities Current LiabilitiesCurrent	11810000	USD
CY2018Q1	us-gaap	Liabilities Current LiabilitiesCurrent	10973000	USD
CY2017Q4	us-gaap	Long Term Loans Payable LongTermLoansPayable	21042000	USD
CY2018Q1	us-gaap	Long Term Loans Payable LongTermLoansPayable	21127000	USD
CY2018Q1	us-gaap	Long Term Loans Payable LongTermLoansPayable	21042000	USD
CY2017Q1	us-gaap	Marketable Securities Unrealized Gain Loss MarketableSecuritiesUnrealizedGainLoss	15000	USD
CY2018Q1	us-gaap	Marketable Securities Unrealized Gain Loss MarketableSecuritiesUnrealizedGainLoss	3000	USD
CY2017Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-292000	USD
CY2018Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	51000	USD
CY2017Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-16532000	USD
CY2018Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	945000	USD
CY2017Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-15316000	USD
CY2018Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-13409000	USD
CY2017Q1	us-gaap	Net Income Loss NetIncomeLoss	-15134000	USD
CY2018Q1	us-gaap	Net Income Loss NetIncomeLoss	-15888000	USD
CY2017Q1	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-15134000	USD
CY2018Q1	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-15888000	USD
CY2018Q1	us-gaap	Number Of Operating Segments NumberOfOperatingSegments	1	segment
CY2017Q1	us-gaap	Operating Expenses OperatingExpenses	14919000	USD
CY2018Q1	us-gaap	Operating Expenses OperatingExpenses	15813000	USD
CY2017Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	617000	USD
CY2018Q1	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	714000	USD
CY2017Q1	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	123000	USD
CY2018Q1	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	19000	USD
CY2018Q1	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	22000	USD
CY2017Q1	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	15000	USD
CY2018Q1	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	3000	USD
CY2017Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	1201000	USD
CY2018Q1	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	1372000	USD
CY2018Q1	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	1201000	USD
CY2018Q1	us-gaap	Other Than Temporary Impairment Losses Investments Availableforsale Securities OtherThanTemporaryImpairmentLossesInvestmentsAvailableforsaleSecurities	0	USD
CY2017Q1	us-gaap	Paid In Kind Interest PaidInKindInterest	144000	USD
CY2017Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-14782000	USD
CY2018Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-15813000	USD
CY2018Q1	us-gaap	Operating Leases Future Minimum Payments Due OperatingLeasesFutureMinimumPaymentsDue	2942000	USD
CY2018Q1	us-gaap	Operating Leases Future Minimum Payments Due In Three Years OperatingLeasesFutureMinimumPaymentsDueInThreeYears	375000	USD
CY2018Q1	us-gaap	Operating Leases Future Minimum Payments Due In Two Years OperatingLeasesFutureMinimumPaymentsDueInTwoYears	1482000	USD
CY2018Q1	us-gaap	Operating Leases Future Minimum Payments Remainder Of Fiscal Year OperatingLeasesFutureMinimumPaymentsRemainderOfFiscalYear	1085000	USD
CY2017Q1	us-gaap	Operating Leases Rent Expense Net OperatingLeasesRentExpenseNet	500000	USD
CY2018Q1	us-gaap	Operating Leases Rent Expense Net OperatingLeasesRentExpenseNet	500000	USD
CY2018Q1	us-gaap	Paid In Kind Interest PaidInKindInterest	177000	USD
CY2017Q1	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	58000	USD
CY2018Q1	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	192000	USD
CY2017Q1	us-gaap	Payments To Acquire Short Term Investments PaymentsToAcquireShortTermInvestments	16474000	USD
CY2018Q1	us-gaap	Payments To Acquire Short Term Investments PaymentsToAcquireShortTermInvestments	13908000	USD
CY2017Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2018Q1	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2017Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000	shares
CY2018Q1	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000	shares
CY2017Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2018Q1	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2017Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2018Q1	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2017Q4	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2018Q1	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2017Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	1979000	USD
CY2018Q1	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	1789000	USD
CY2018Q1	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	2210000	USD
CY2017Q1	us-gaap	Proceeds From Maturities Prepayments And Calls Of Shortterm Investments ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments	0	USD
CY2018Q1	us-gaap	Proceeds From Maturities Prepayments And Calls Of Shortterm Investments ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments	15045000	USD
CY2017Q1	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	436000	USD
CY2018Q1	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	0	USD
CY2017Q1	us-gaap	Proceeds From Stock Plans ProceedsFromStockPlans	0	USD
CY2018Q1	us-gaap	Proceeds From Stock Plans ProceedsFromStockPlans	51000	USD
CY2017Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	6249000	USD
CY2018Q1	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	2257000	USD
CY2018Q1	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	2091000	USD
CY2018Q1	us-gaap	Realized Investment Gains Losses RealizedInvestmentGainsLosses	0	USD
CY2018Q1	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	6590000	USD
CY2017Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	2091000	USD
CY2017Q1	us-gaap	Repayments Of Long Term Debt RepaymentsOfLongTermDebt	728000	USD
CY2018Q1	us-gaap	Repayments Of Long Term Debt RepaymentsOfLongTermDebt	0	USD
CY2017Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	11044000	USD
CY2018Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	11139000	USD
CY2017Q1	us-gaap	Restricted Cash And Cash Equivalents At Carrying Value RestrictedCashAndCashEquivalentsAtCarryingValue	81000	USD
CY2018Q1	us-gaap	Restricted Cash And Cash Equivalents At Carrying Value RestrictedCashAndCashEquivalentsAtCarryingValue	76000	USD
CY2017Q1	us-gaap	Restricted Cash And Cash Equivalents Noncurrent RestrictedCashAndCashEquivalentsNoncurrent	316000	USD
CY2018Q1	us-gaap	Restricted Cash And Cash Equivalents Noncurrent RestrictedCashAndCashEquivalentsNoncurrent	329000	USD
CY2017Q4	us-gaap	Restricted Cash And Investments Noncurrent RestrictedCashAndInvestmentsNoncurrent	329000	USD
CY2018Q1	us-gaap	Restricted Cash And Investments Noncurrent RestrictedCashAndInvestmentsNoncurrent	2696000	USD
CY2018Q1	us-gaap	Restricted Cash And Investments Noncurrent RestrictedCashAndInvestmentsNoncurrent	2696000	USD
CY2017Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-216900000	USD
CY2017Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-216897000	USD
CY2018Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-228400000	USD
CY2018Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-228357000	USD
CY2018Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-212469000	USD
CY2018Q1	us-gaap	Revenue Remaining Performance Obligation RevenueRemainingPerformanceObligation	8600000	USD
CY2018Q1	us-gaap	Revenue Remaining Performance Obligation Expected Timing Of Satisfaction Period RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod	P12M
CY2017Q1	us-gaap	Revenues Revenues	137000	USD
CY2018Q1	us-gaap	Revenues Revenues	0	USD
CY2018Q1	us-gaap	Sale Of Stock Number Of Shares Issued In Transaction SaleOfStockNumberOfSharesIssuedInTransaction	22349840	shares
CY2017Q4	us-gaap	Short Term Investments ShortTermInvestments	25940000	USD
CY2018Q1	us-gaap	Short Term Investments ShortTermInvestments	24839000	USD
CY2018Q1	us-gaap	Short Term Investments ShortTermInvestments	25940000	USD
CY2018Q1	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	0	shares
CY2017Q4	us-gaap	Stockholders Equity StockholdersEquity	51814000	USD
CY2018Q1	us-gaap	Stockholders Equity StockholdersEquity	41582000	USD
CY2018Q1	us-gaap	Stockholders Equity StockholdersEquity	56242000	USD
CY2018Q1	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	0	USD
CY2018Q1	us-gaap	Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued	0	USD
CY2018Q1	us-gaap	Unrecognized Tax Benefits Interest On Income Taxes Accrued UnrecognizedTaxBenefitsInterestOnIncomeTaxesAccrued	0	USD
CY2017Q1	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	18474227	shares
CY2018Q1	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	22345523	shares
CY2018Q1	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Concentrations of Credit Risk and Off‑Balance Sheet Risk</font></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Financial instruments that potentially subject the Company to concentration of credit risk consist primarily of cash, cash equivalents, and accounts receivable. Cash and cash equivalents are deposited with federally insured financial institutions in the United States and may, at times, exceed federally insured limits. Management believes that the financial institutions that hold the Company’s deposits are financially credit worthy and, accordingly, minimal risk exists with respect to those balances. Generally, these deposits may be redeemed upon demand and therefore bear minimal interest rate risk. As an integral part of operating its Russian subsidiary, the Company also maintains cash in Russian bank accounts in denominations of both Russian rubles and U.S. dollars. As of </font><font style="font-family:inherit;font-size:10pt;">March 31, 2018</font><font style="font-family:inherit;font-size:10pt;">, the Company maintained approximately </font><font style="font-family:inherit;font-size:10pt;">$1.1 million</font><font style="font-family:inherit;font-size:10pt;"> in Russian bank accounts, of which </font><font style="font-family:inherit;font-size:10pt;">$1.0 million</font><font style="font-family:inherit;font-size:10pt;"> was held in U.S. dollars.</font></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company has minimal credit risk as the majority of accounts receivable relates to amounts due under a government sponsored grant, collaboration with large pharmaceutical companies or grants from well‑known and supported non‑profit organizations. The Company did not have any off balance sheet arrangements as of </font><font style="font-family:inherit;font-size:10pt;">March 31, 2018</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">December 31, 2017</font><font style="font-family:inherit;font-size:10pt;">.</font></div></div>
CY2018Q1	us-gaap	Use Of Estimates UseOfEstimates	<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Use of Estimates</font><font style="font-family:inherit;font-size:10pt;"> </font></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The preparation of consolidated financial statements in conformity with U.S. GAAP requires the Company’s management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. The Company’s management considers many factors in selecting appropriate financial accounting policies and controls, and bases its estimates on historical experience and other market-specific or other relevant assumptions that it believes to be reasonable under the circumstances. In preparing these consolidated financial statements, management used significant estimates in the following areas, among others: revenue recognition, the fair value of common stock and other equity instruments, accounting for stock-based compensation and estimating accrued research and development expenses. The Company assesses the above estimates on an ongoing basis; however, actual results could materially differ from those estimates.</font></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;"></font></div></div>

Files In Submission

Name	View Source	Status
0001453687-18-000030-index-headers.html	Edgar Link	pending
0001453687-18-000030-index.html	Edgar Link	pending
0001453687-18-000030.txt	Edgar Link	pending
0001453687-18-000030-xbrl.zip	Edgar Link	pending
exhibit311_3312018.htm	Edgar Link	pending
exhibit312_3312018.htm	Edgar Link	pending
exhibit321_3312018.htm	Edgar Link	pending
exhibit322_3312018.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R64.htm	Edgar Link	pending
R65.htm	Edgar Link	pending
R66.htm	Edgar Link	pending
R67.htm	Edgar Link	pending
R68.htm	Edgar Link	pending
R69.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R70.htm	Edgar Link	pending
R71.htm	Edgar Link	pending
R72.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
selb-20180331.xml	Edgar Link	completed
selb-20180331.xsd	Edgar Link	pending
selb-20180331_cal.xml	Edgar Link	unprocessable
selb-20180331_def.xml	Edgar Link	unprocessable
selb-20180331_lab.xml	Edgar Link	unprocessable
selb-20180331_pre.xml	Edgar Link	unprocessable
selectabiosciences10-q33118.htm	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$RNAC
Cartesian Therapeutics, Inc. Stock $rnac

2018 Q2 Form 10-Q Financial Statement

#000145368718000030 Filed on May 09, 2018

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$RNAC Cartesian Therapeutics, Inc. Stock $rnac

2018 Q2 Form 10-Q Financial Statement

#000145368718000030 Filed on May 09, 2018

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$RNAC
Cartesian Therapeutics, Inc. Stock $rnac